Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

The company’s sole marketed product, Nerlynx (neratinib), is approved for treating early-stage HER2-positive breast cancer in patients previously treated with Roche’s RHHBY Herceptin-based ...

In a separate development, Puma Biotechnology has asked the CHMP to rethink its decision to reject breast cancer drug Nerlynx (neratinib) last month. Companies may apply for a re-examination of a ...

The biotech already sells one drug for HER2-positive breast cancer – oral HER2 inhibitor Nerlynx (neratinib) – and its main R&D focus is on extending its use into multiple breast cancer settings.

We are currently studying whether an orally active protein kinase C beta inhibitor (ruboxistaurin) and a clinical EGFR/ErbB inhibitor (neratinib) have therapeutic potential in lung and cardiovascular ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22 ...

Investing.com – Wall Street was set to push forward to new record highs on Thursday as investors waited for key corporate... By Alana Wise NEW YORK (Reuters) - American Airlines (O:AAL) and ...